Education
About Us
Working with TipRanks
Follow Us
Capha Pharmaceuticals Inc. (FPSUF)
OTHER OTC:FPSUF
RESEARCH TOOLSreports
Top Page
Capha Pharmaceuticals
(OTC:FPSUF)
Rating:37Underperform
Price Target:―
Capha Pharmaceuticals (FPSUF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$64.00
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.00
Revenue GrowthN/A
EPS Growth22.22%
CountryUS
EmployeesN/A
SectorHealthcare
Sector Strength49
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding64,431,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Capha Pharmaceuticals Business Overview & Revenue Model
Company DescriptionCapha Pharmaceuticals (FPSUF) is a biopharmaceutical company that specializes in the research, development, and commercialization of innovative medicines. The company operates within the healthcare sector, focusing primarily on the creation of therapeutic solutions for unmet medical needs. Capha Pharmaceuticals is committed to advancing medical science through its cutting-edge drug development programs and collaborations with leading research institutions.
How the Company Makes MoneyCapha Pharmaceuticals generates revenue primarily through the sale of its proprietary pharmaceutical products. The company invests heavily in research and development to bring new drugs to market, which are then commercialized and distributed globally. Key revenue streams include direct sales to healthcare providers, licensing agreements, and strategic partnerships with other pharmaceutical companies. Additionally, Capha Pharmaceuticals may receive milestone payments and royalties from collaborations with partners who leverage its research and development capabilities. The company's earnings are also supported by its intellectual property portfolio, which provides competitive advantages and potential for long-term revenue generation.
Capha Pharmaceuticals Financial Statement Overview
Summary
Capha Pharmaceuticals faces significant financial challenges, marked by zero revenue, escalating losses, and high leverage. The absence of revenue generation and reliance on debt financing underscore a precarious financial position, posing considerable risks.Income Statement
Capha Pharmaceuticals shows no revenue generation across all periods, leading to a lack of profitability. The consistent negative figures for EBIT and Net Income indicate persistent operational losses without revenue growth potential.1
Very Negative
Balance Sheet
The balance sheet is highly leveraged with a negative stockholders' equity, indicating insolvency risk. Total debt has increased significantly over the years, further heightening financial instability.1
Very Negative
Cash Flow
The company consistently reports negative operating and free cash flows, suggesting insufficient cash generation to cover operations. Financing activities are the primary cash source, indicating reliance on external funding.2
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | ― | ― | ― | ― |
| EBITDA | -58.56K | -50.74K | -53.22K | -57.68K | -44.49K | -50.23K |
| Net Income | -60.22K | -70.77K | -53.36K | -58.31K | -44.81K | -51.16K |
Balance Sheet | ||||||
| Total Assets | 1.82K | 1.80K | 1.75K | ― | ― | ― |
| Cash, Cash Equivalents and Short-Term Investments | 1.38K | 653.00 | 671.00 | ― | ― | ― |
| Total Debt | 560.07K | 560.07K | 489.07K | 416.07K | 338.07K | 276.57K |
| Total Liabilities | 581.27K | 572.32K | 501.49K | 317.34K | 282.01K | 234.27K |
| Stockholders Equity | -579.45K | -570.51K | -499.74K | -315.67K | -278.52K | -232.05K |
Cash Flow | ||||||
| Free Cash Flow | -63.95K | -71.02K | -73.36K | -61.49K | -47.38K | -76.17K |
| Operating Cash Flow | -63.95K | -71.02K | -73.36K | -61.49K | -47.38K | -76.17K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 63.50K | 71.00K | 73.00K | 59.91K | 49.05K | 74.93K |
Capha Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $20.32B | 13.26 | 9.13% | ― | 3.48% | 31.44% | |
73 Outperform | $100.71B | 28.08 | 22.77% | ― | 10.38% | ― | |
72 Outperform | $61.52B | 14.62 | 15.34% | 0.30% | 5.38% | 3.58% | |
68 Neutral | $146.87B | 23.55 | 33.26% | 2.64% | 3.69% | 501.26% | |
66 Neutral | $156.28B | 23.75 | 99.14% | 3.12% | 13.10% | 110.67% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% | |
37 Underperform | $64.00 | ― | 10.68% | ― | ― | 22.22% |
* Healthcare Sector Average
Performance Comparison
FPSUF
Capha Pharmaceuticals
0.01
0.00
0.00%
AMGN
Amgen
296.47
-23.46
-7.33%
BIIB
Biogen
138.60
-67.46
-32.74%
GILD
Gilead Sciences
118.37
46.25
64.13%
REGN
Regeneron
580.41
-613.17
-51.37%
VRTX
Vertex Pharmaceuticals
392.79
-95.26
-19.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.